Bristol’s Opdivo Is First Checkpoint Inhibitor Cleared For Blood Cancer

FDA granted Opdivo an ultra-rapid approval for the treatment of classical Hodgkin lymphoma that has relapsed or progressed, making it the first PD-1 inhibitor approved for hematological cancer.